title: Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma.
authors.affiliation: Medizinische Klinik und Poliklinik II, Julius Maximilians Universität Würzburg, Würzburg, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Einsele
authors.affiliation: Medizinische Klinik und Poliklinik II, Julius Maximilians Universität Würzburg, Würzburg, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Knop
authors.affiliation: Janssen-Cilag GmbH, Neuss, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Vogel
authors.affiliation: Acromion GmbH, Frechen, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Müller
authors.affiliation: Universitätsklinikum Münster, Münster, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Kropff
authors.affiliation: Klinikum Oldenburg Klinik für Onkologie und Hämatologie, Oldenburg, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Metzner
authors.affiliation: Zentrum für Innere Medizin Universitätsklinikum Ulm, Ulm, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Langer
authors.affiliation: University Hospital Jena, Jena, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Sayer
authors.affiliation: Onkologie Universitätsmedizin Göttingen, Göttingen, Germany.
authors.forename: W
authors.initials: W
authors.lastname: Jung
authors.affiliation: St Marien Hospital Hamm Knappenstraße, Hamm, Germany.
authors.forename: H A
authors.initials: HA
authors.lastname: Dürk
authors.affiliation: Asklepios Klinik Altona, Hamburg, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Salwender
authors.affiliation: Medizinische Klinik 5-Hämatologie und Onkologie, Nürnberg, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Wandt
authors.affiliation: Technische Universität München Medizinische Klinik, München, Germany.
authors.forename: F
authors.initials: F
authors.lastname: Bassermann
authors.affiliation: Universitätsklinikum Schleswig-Holstein, Kiel, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Gramatzki
authors.affiliation: Universitätsklinkum Erlangen, Erlangen, Germany.
authors.forename: W
authors.initials: W
authors.lastname: Rösler
authors.affiliation: University Hospital Halle, Halle (Saale), Germany.
authors.forename: H-H
authors.initials: HH
authors.lastname: Wolf
authors.affiliation: Schwarzwald-Baar Klinikum, Villingen-Schwenningen, Germany.
authors.forename: W
authors.initials: W
authors.lastname: Brugger
authors.affiliation: University of Freiburg, Freiburg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Engelhardt
authors.affiliation: Otto-von-Guericke University, Magdeburg, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Fischer
authors.affiliation: Zentrum für Innere Medizin Universitätsklinikum Ulm, Ulm, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Liebisch
authors.affiliation: Schön Klinik Starnberger See, Berg, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Straka
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000069286:Bortezomib / Q000009:adverse effects / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D060830:Consolidation Chemotherapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009101:Multiple Myeloma / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous
chemical_list: D000970:Antineoplastic Agents; D000069286:Bortezomib